Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 1Healthy, no Evidence of Disease 1Breast Neoplasms 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × 3,3'-diindolylmethane × Clear all
NCT01022333 2009-12-01

The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

Women's College Hospital

Phase 1 Unknown
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡